Product Reports Resources Pricing Login Book a demo

Ocular Therapeutix

Biotech & Life Sciences · Bedford, United States · Founded 2006 · IPO 2014

Biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye

Valuation $1.20B
Revenue $52M

Investors

15 investors on Ocular Therapeutix's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 15 investors entered at this stage
Great Point Partners
Acuta Capital Partners
Versant Ventures
Ascension Ventures
SV Health Investors
Opaleye Management
Deep Track Capital
Baxter International
Ascension
TCGX
Logos Capital
Polaris Partners
Surveyor Capital
Venrock Healthcare Capital Partners
Perceptive Advisors

Global footprint

Where Ocular Therapeutix has talent and traffic

Workforce by country
🇺🇸 United States · Bedford HQ
Book a demo for the full country breakdown
Web traffic by country
11K monthly visits
across markets
🇺🇸 United States70.9%
🇮🇳 India15.5%
🇧🇪 Belgium8.2%
🇨🇦 Canada6.4%
🇩🇪 Germany1.8%
Top 5 markets shown

Talent graph

The shape of Ocular Therapeutix's talent

Dealroom maps Ocular Therapeutix's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Ocular Therapeutix's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$31M patent portfolio · 34 active families

Estimated portfolio value
$31M
2.6% of market cap · 17.6× smaller than top peer ChemoCentryx ($550M)
34 active patent families
Where Ocular Therapeutix innovates BiodegradationBiologyBiomedical engineeringImplantOcular disease

Where Ocular Therapeutix concentrates vs peers

Each axis is a top-10 topic across Ocular Therapeutix and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Ocular Therapeutix

An AI-synthesized read of the highest-engagement posts about Ocular Therapeutix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ocular Therapeutix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.